---
figid: PMC11214464__gr4
pmcid: PMC11214464
image_filename: gr4.jpg
figure_link: /pmc/articles/PMC11214464/figure/fig4/
number: Fig. 4
figure_title: ''
caption: Co-treatment with BAY-598 and DOX inhibits lung cancer cell growth through
  the NFκB and JAK-STAT signaling pathway. (A). Western blotting showing expression
  levels of P-p65, p65, P-STAT3, STAT3, P-ERK, ERK, P-MTOR, MTOR in A549 cells. (B).
  Western blotting showing expression levels of P-p65, p65, P-STAT3, STAT3, P-ERK,
  ERK, P-MTOR, MTOR in H460 cells. (C, D) Pathway-related Protein Quantification,
  The protein densities were analyzed with ImageJ. (*P < 0.05, **P < 0.01, ***P < 0.001,
  ****P < 0.0001).
article_title: Synergistic anticancer effects of SMYD2 inhibitor BAY-598 and doxorubicin
  in non-small cell lung cancer.
citation: Jiaqi Meng, et al. Heliyon. 2024 Jun 15;10(11):e32015.
year: '2024'

doi: 10.1016/j.heliyon.2024.e32015
journal_title: Heliyon
journal_nlm_ta: Heliyon
publisher_name: Elsevier

keywords:
- NSCLC
- DOX
- JAK/STAT signaling
- BAY-598

---
